Revolution Medicines' pancreatic cancer drug wins FDA approval, validating long-sought mechanism
The FDA approved Rasonque, a once-daily pill for metastatic pancreatic cancer, developed by Revolution Medicines. The drug targets the RAS protein, previously considered undruggable, and doubled median survival compared to chemotherapy. Investors see this as proof that the mechanism works, potentially opening doors for broader cancer treatments.
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet.” Browse more stories.